| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 2.6K | 21.6% | 36.4% |
| Total Income | 2.6K | 21.8% | 35.4% |
| Expenditure | 2.1K | 16.3% | 20.7% |
| PBT | 467.63 | 55.2% | 202.2% |
| Net Profit | 345.01 | 56.9% | 207.4% |
| OPM | 20.96% | 3.23pp | 10.93pp |
| NPM | 13.31% | 2.98pp | 7.45pp |
| EPS | 25.30 | 57.0% | 207.4% |
Record Earnings, But April Shutdown Raises Sustainability Questions
Deepak Nitrite delivered all-time high PAT of ₹345 crore (+207% YoY), but the quarter leaned heavily on volatile raw material sourcing. April's plant shutdown and propylene scarcity hint that the run-rate was hit only at specific periods, not sustained.
₹2,578 Cr
+36.4% YoY; +21.6% QoQ
₹345 Cr
+207.4% YoY; +56.9% QoQ
21%
+10pp YoY (vs 11%)
23.5%
record; ₹418 Cr EBIT
The headline numbers tell one story: Deepak Nitrite hit all-time highs across revenue, PAT, and EBITDA in Q1 FY-2027, delivering ₹345 crore in net profit—a 207% surge from a year ago. On the surface, this is a blowout. But the earnings call reveals the ground truth: the quarter benefited from a narrow window of favorable conditions (raw material sourcing, demand strength, low inventory carry costs) that proved unsustainable by April. The real question isn't whether Q1 was a record—it was—but whether that record represents a new baseline or a peak inflated by transient tailwinds.
The tension: record profitability, but April signals moderation
Management opened the call emphasizing "record profitability" and operational excellence, but the detail tells a more nuanced story. The company achieved a phenol run-rate of approximately 1 lakh tonnes per quarter, a milestone milestone toward the 4-lakh-tonne annual target. Yet management later clarified this was achieved only on a "run rate basis"—meaning there were "significant periods" where the company hit that number, but other periods where it did not, due to propylene sourcing constraints and a plant shutdown in April. When pressed by analysts, Maulik Mehta (CFO) acknowledged: "There were significant periods during the quarter where we came to that number on a run rate basis. There were periods where we did not because of raw material sourcing."
April weakness is the canary in the coal mine. The company faced a maintenance shutdown (preponed from Q2) and a propylene supply squeeze coinciding with global tightness. While management framed this as a one-off, it exposes the fragility of the margin story: phenolics delivered a record EBIT margin of 23.5%, but this was driven almost entirely by backward-integrated supply chain management and favorable propylene pricing relative to peers. If that arbitrage closes—or if propylene supply tightens further—margin durability becomes the key risk.
Record PAT of ₹345 Cr, +207% YoY
Delivered ₹345.0 Cr. YoY growth verified at +207.4%.
Supported
Revenue ₹2,592 Cr, 35% YoY growth
Actual ₹2,577.6 Cr (call overstated by ₹14.4 Cr). YoY growth 36.4%, not 35%.
Slightly overstated
EBITDA ₹554 Cr, 21% margin
Implies PAT + depreciation + tax + interest range ≈ ₹500–550 Cr; 21% OPM confirmed.
Supported
Phenol run-rate of 1 lakh tonnes achieved in Q1
Clarified as 'run rate basis' only. April weak due to shutdown + propylene shortage. Not a sustained quarterly volume.
Overstated
Strong inventory management benefited Q1 working capital
Management later stated: 'I don't think there was any place where we were able to get any benefit' from inventory in Q1.
Contradicted
What changed on this call
Ammonia-to-amines integration complete: The company is no longer a 'nitration company that buys nitric acid'—now a 'nitrogen company that nitrates.' This unlocks downstream diazotization, fluorination, and amination businesses, creating a structural moat.
Phenol capacity roadmap clarified: Debottlenecking trajectory from ~3.5L tonne maturity to 4L tonne annual target, with advanced process controls investment of ₹70–100 crore. MIBC capacity exceeded design spec in pre-commissioning runs.
Capex funding closed: ₹11.5 crore polycarbonate/propylene project funded via debt at 'competitive rates' (80% of capex). 60:40 debt:equity; peak debt ₹8–8.5 crore. Financial flexibility confirmed.
R&D timeline extended: Flow chemistry, fluorination, amination benefits pushed to 'next FY, not this FY.' Customer validation cycles 12–24+ months. Margin upside deferred.
The bull-bear ledger
All-time high PAT, EBITDA, and revenue delivered in Q1
Integrated asset ramp driving tangible operational leverage (AI EBIT margin +89% YoY)
Ammonia-to-amines integration complete; unlocks high-margin downstream chemistry
Capex funding for ₹11.5 Cr projects closed; debt-to-equity <1x (comfortable leverage)
Phenol 4L tonne roadmap now concrete; debottlenecking strategy and ₹70–100 Cr further investment planned
Reported margins (21% EBITDA, 23.5% phenolics EBIT) heavily dependent on volatile raw material sourcing arbitrage
Phenol 1L tonne run-rate achieved only on 'run rate basis'; April shutdown + propylene scarcity hint unsustainability
Inventory benefit narrative contradicted; management later admitted 'no place' to extract working capital benefit
Management refused to quantify MIBK/MIBC margin profiles; opacity raises credibility concerns on new asset returns
Project execution risk high: ₹11.5 Cr capex, phased commissioning (MIBK/MIBC Q2, polycarbonate H2 FY28-29)
Risks, ranked by how much they should concern a holder
Raw material volatility and supply disruption
HighQ1 benefited from management's agility in propylene sourcing, but April shutdown + shortage shows the fragility. Phenol EBIT margin 23.5% heavily reliant on RM cost arbitrage vs. public indices. If propylene tightens or pricing normalizes, margins erode significantly.
Phenol run-rate unsustainability and capacity constraints
High1L tonne/qtr achieved only on 'run rate basis' with April weak. Quarterly volume sustainability unclear. The 4L tonne annual target requires debottlenecking success and removal of seasonal winter/summer delta—both unproven at scale.
Project execution delays (capex, commissioning timelines)
High₹11.5 Cr capex phased across FY27-29. MIBK/MIBC ramp by Q2; polycarbonate H2 FY28-29. Delays cascade; each quarter of delay pushes margin accretion further out and ties up capital longer.
R&D pipeline commercialization lag
MediumFlow chemistry, fluorination, amination benefits pushed to 'next FY, not this FY.' Customer validation cycles 12–24+ months. Near-term margin upside muted; long-term IRR depends on successful customer adoption.
Margin profile opacity on new assets (MIBK/MIBC, PC)
MediumManagement refused to quantify MIBK/MIBC or polycarbonate margin profiles—only stated 'inline or better than average AI.' This defensiveness raises credibility concerns: are margins disappointing or held strategically? Lack of clarity erodes analyst confidence in earning power.
Geopolitical disruption and import duty swings
MediumQ1 operated under duty-free phenol imports; Q2 onwards, duty reimposed. Pricing support but also signals macro demand volatility. Freight, insurance rates elevated (Middle East premium). 15% export revenue exposed to these headwinds.
How the street is positioned
The stock's price action in the days following the result reveal the market's own verdict on the print: a day-1 pop of +0.96% steadily built to +4.35% by day 3, holding at +3.23% by day 5. This measured ascent—neither a sharp spike nor a fade—suggests the street is cautiously bullish on the headline, but skeptical on sustainability. The stock now trades at ₹1,771, above its 20-day (₹1,714.22), 50-day (₹1,668.7), and 200-day (₹1,632.34) moving averages, signaling an established uptrend. However, at a -6.69% drawdown from its all-time high and +38.36% off its 52-week low, the stock is neither deeply oversold nor richly extended. RSI at 62.8 sits neutral—room to run either direction.
Ownership remains stable: FII holdings at 6.25%, DII at 23.76%, promoter at 49.34%. Quarter-on-quarter, FII added 6bp, DII added 29bp, and promoter was flat. This is not aggressive institution buying, nor is it trimming. Steady hands holding. The lack of bulk/block selling near the all-time high (and the promoter's unchanged stake) suggests insiders are not signaling distress—a positive read.
The reconciliation: fundamentally, the record Q1 is real, but the market is pricing it as a peak, not a new floor. The cautious post-result run-up reflects this: the street wants to own the story but remains uncertain whether April's weakness is a blip or a harbinger. That ambiguity is priced into the modest post-result outperformance.
1 · Q2 phenol volumes and EBITDA margin
Will phenol sustain 1L tonne run-rate post-April? Will EBITDA margin (21% in Q1) hold, decline, or re-expand as propylene supply improves? This is the linchpin for baseline assumptions. If volumes sink or margins fall >200bp, the record quarter was a peak, not a step-change.
2 · MIBK/MIBC commissioning and margin realization (Q2–Q3)
Product quality approved, but ramp timeline and actual EBIT margin realization are unproven at scale. Early customer feedback and volumes in Q2 will show whether management's confidence is warranted or optimistic. Margin profile details matter for earnings sustainability.
3 · Flow chemistry and R&D commercialization pipeline (FY28+)
Expected benefits deferred to 'next FY, not this FY.' Customer validation timelines (typically 12–24 months) and economic contribution will determine whether R&D investments compound into structural margin upside or remain a cost center. Proof-of-concept wins will be the early signal.
Deepak Nitrite's Q1 FY-2027 is genuinely a record. All-time high PAT, EBITDA, revenue; record phenolics margins; integration assets ramping. But the quarter benefited from a narrow window of favorable conditions (RM arbitrage, demand strength, inventory carry tailwinds) that proved unsustainable by April. Management's clarification that the phenol 1L tonne/qtr run-rate was achieved only on a "run rate basis"—with April weak and visibility into Q2 limited—raises an honest sustainability question.
This is not a step-change; it is steady execution with a cyclical peak. The long-term upside (ammonia-to-amines done, ₹11.5 Cr capex on track, 4L tonne phenol + polycarbonate by H2 FY28-29) is real. But near-term, the burden of proof falls on management to show Q2-Q3 baseline earnings (sans the RM tailwinds) and early proof on capex commissioning and MIBK/MIBC ramps.
Verdict: Hold. The rating assumes record Q1 was a peak, April signals moderation, and project execution delivers. The single number to track from here is Q2 adjusted EBITDA (excluding any RM sourcing benefits)—if it holds >18%, the run-rate is credible; if it sinks toward 15%, rebase expectations downward. Until then, own for the structural upside but stay cautious on cyclical margin peaks.
Margin Momentum in Motion — What Q1 FY27 Will Signal
Deepak Nitrite enters Q1 FY27 with a margin recovery in train and capex ambitious for specialty chemicals. The quarter will test whether Q4's 18% EBITDA margin holds, and whether the street's 21–36% upside thesis rests on execution.
What to Expect
~₹1,650 Cr
Q1 typically lower than Q4; prior analyst range ₹1,566–1,763 Cr. Last year Q1 FY26 was ₹1,809 Cr.
~17–19%
Q4 FY26 delivered 18%; FY26 full-year average was 13%. Watch for sustainability of the recovery.
~₹280–315 Cr
Indexed off expected revenue and margin. FY26 full-year EBITDA was ₹1,041 Cr (~13% margin).
Watch for
Q4 FY26 PAT was ~₹290 Cr. Q1 typically reflects seasonal softness and higher finance costs.
A strong Q1 would hold margins above 17%—confirming that Q4's operational leverage (higher utilization, pricing discipline) is structural, not transient. Revenue in the ₹1,700+ Cr range would suggest no seasonal cliff and export traction. A weak Q1 would show margin compression below 16%, signaling that Q4's margin beat was offset by lower volumes or raw-material headwinds. Revenue below ₹1,550 Cr would raise questions about export demand and volume sustainability heading into the capex cycle.
On Track with Guidance?
Management guided to margin improvement in FY27 vs FY26, with expectations for both standalone and consolidated performance to improve as the company progresses. Q4 FY26's 18% EBITDA margin is the proof point—a jump from Q3's 11% and well above the full-year 13% average. Q1 FY27 will be the first test: if margins hold in the 17–19% zone, it confirms the guidance is credible. Volumes matter too. The company is ramping specialty chemicals (higher-margin fluorination and fine-chemistry outputs) and has commenced capex on new downstream facilities. A flat-to-up Q1 revenue would signal that demand is holding despite macro softness in Europe.
What the Street Says
Since Last Quarter
Strategic capex and subsidiary moves dominate the filing scan. Deepak Chem Tech Limited (DCTL, the wholly-owned subsidiary driving new chemistry projects) has raised ₹120 Cr in 9% Optionally Convertible Redeemable Preference Shares, allocated to Deepak Phenolics—signaling debt-light funding for the HyCO plant (hydrogen-carbon monoxide synthesis, raw material for downstream fine chemicals). Deepak Nitrite itself has guaranteed a $78.43 M Term Loan for Deepak Oman Industries, a subsidiary, to fund operations and capex in Oman—a strategic bet on non-India diversification. Neither is a red flag; both are normal for specialty-chemical capex. Promoter holding flat at 49.33%, DII slightly up to 23.47%, FII stable at 6.19%—no insider selling or pledging. AGM scheduled for Aug 5, with director reappointments and dividend approval (FY26 dividend ₹7.50/share). Earnings call Aug 6 at 3:30 PM IST.
Key Watchpoints for Aug 4
1 · Can Q1 EBITDA margin hold 17–19%?
The most important line. Q4's 18% is the new watermark; if Q1 delivers above 16.5%, the Street's confidence in FY27 margin guidance strengthens. Below 15.5% and the capex thesis gets questioned.
2 · Revenue trajectory: ₹1,550–1,750 Cr or cliff?
Volume and pricing are the tells. In-range delivery confirms export demand and pricing power are intact; a miss raises questions about macro headwinds.
3 · Capex progress and phasing
Management will discuss the ₹1,500–2,000 Cr fine-chemicals and fluorination capex plan. How much is committed by Q1, and when are first earnings accretions expected? A clear schedule is key to credibility.
4 · FY27 full-year margin and revenue guidance
Will management quantify the margin band for FY27? Consensus is 17–20% sustainable, but specificity matters. Any revisit to the guidance would signal macro or market anxiety.
5 · Dividend sustainability & capital allocation
FY26 dividend was ₹7.50/share (375% payout). With capex ramping, watch for commentary on dividend sustainability and buyback plans. Retail investors will parse this.
In Summary
Deepak Nitrite is at an inflection: Q4 FY26 proved operational leverage in specialty chemicals (18% EBITDA margin vs 13% full-year average), and FY27 is when the capex cycle begins in earnest. The street prices in 21–36% upside on the bet that fine chemicals and fluorination products will sustain 17–20% margins as they scale. Q1 FY27 is not the capex payoff quarter—it's the margin hold-or-break quarter. Revenue in the ₹1,650 Cr zone with EBITDA margin above 17% would signal that the beat is real, not one-off. A miss on either front, and the narrative shifts to execution risk. Watch the earnings call carefully for capex phasing and FY27 guidance specificity; that's where the real debate is.
Record earnings, margin durability in question amid capex ramp
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q1 numbers hit targets; prior guidance vague (no numeric FY27 goal). April weakness suggests Q1 peaks, not baselines. Capex funding closed (debt raised)—execution now critical.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Record Q1 earnings (₹345 Cr PAT, 21% EBITDA margin) driven by integrated assets ramping, favorable RM sourcing, and operational excellence. However, sustainability questions: April saw plant shutdown + propylene scarcity, phenol run-rate of 1L tonne/qtr hit only on run-rate basis, margin expansion reliant on volatile RM costs. Capex-heavy trajectory (₹11.5 Cr polycarbonate) and project execution risk (FY28-29 timeline) warrant caution despite long-term upside.
₹2592 Cr
Revenue · +35% YoY₹345 Cr
Reported PAT · +207% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Record PAT of ₹345 Cr, +207% YoY
METDelivered ₹345.0 Cr, confirmed YoY growth +207.4%
Revenue ₹2,592 Cr, 35% YoY growth
OVERSTATEDDelivered ₹2,577.6 Cr; call slightly overstated by ₹14.4 Cr. Actual YoY 36.4%, not 35%
EBITDA ₹554 Cr, 159% YoY growth, 21% margin
METImplies PAT+D+Tax+Interest ≈ ₹500-550 range; OPM 21% confirmed. No EBITDA breakdown given but plausible
Phenol run-rate of 1 lakh tonnes achieved in Q1
OVERSTATEDClarified as 'run rate basis' only, April weak due to shutdown + propylene shortage. Not a sustained quarterly volume
Inventory management benefit in Q1
MISSManagement later stated: 'I don't think there was any place where we were able to get any benefit' from inventory
Earnings quality
What changed since the last call
Ammonia-to-amines integration complete
NewNo longer 'nitration company that buys nitric acid'; now 'nitrogen company that nitrates.' Strategic shift unlocks downstream chemistry (diazotization, fluorination). Announced on call; tangible moat.
Phenol capacity debottlenecking trajectory
UpgradeFrom ~3.5L tonne 'maturity' to 4L tonne target via advanced process controls + ₹70-100 Cr further invest. Prior call vague; now concrete roadmap. MIBC capacity exceeded design spec in pre-comm runs.
Capex funding closed
New₹11.5 Cr propylene/polycarbonate project debt tied up at 'competitive rates.' 60:40 debt:equity; peak debt ₹8-8.5 Cr, D/E <1x. Financial flexibility confirmed.
R&D commercialization timeline extended
DowngradeFlow chemistry benefits 'next FY, not this FY.' Fluorination, amination still in customer validation (months to 12+ months cycles). Margin upside deferred.
Phenol import duty re-imposed; supply-demand tightening
NeutralQ1 operated under duty-free imports; Q2+ duty back on phenol. Government recognition of domestic supply adequacy. Supports pricing but also signals macro demand volatility.
The Q&A
Analysts pressed hard on margin sustainability (spreads), phenol run-rate credibility, and MIBK/MIBC ramp timeline. Management held ground—declined to quantify spreads (prudent) but reaffirmed operational excellence and product quality approval. Refused margin guidance on new assets (defensive). On exports/freight volatility, provided examples of agile customer engagement (sodium nitrite formulation change to lower hazmat class). Tone was confident but guarded on specifics.
Phenol capacity, run-rate — Nirav Jimudia, Anvil Wealth
PartialRun rate basis only in Q1; April weak (shutdown + propylene shortage). 'Significant periods' at run rate, but not constant. Aiming for 4L tonne target via debottlenecking, reducing summer-winter delta.
Phenolics spreads sustainability — Sanjesh Jain, ICICI Securities
DodgedDeclined to comment on spreads; highlighted operational excellence on RM sourcing vs public indices. Stated achieved prices 'better than reflected on international index.'
MIBK, MIBC approval & ramp — Sanjesh Jain, ICICI Securities
AnsweredProduct quality approved, best-in-class. Pre-comm runs met target RM & utility norms. Confident of 100%+ ramp very quickly. Common OSBLs will uplift site profitability.
AI margin profile on new projects — Nirav Jimudia, Anvil Wealth
DodgedRefrained from quantifying. Stated margins 'inline or better than average margin profile of AI.' Integrated asset fungibility provides upside.
Polycarbonate project commissioning timeline — Archit Joshi, Nuvama Wealth
AnsweredPhenol aligned with PDH propylene supply. Polycarbonate disengaged; targeting H2 FY28-29 (clarified FY28-29, not FY28). BPA couple months after. Balancing pace vs not losing market share.
Raw material sourcing for Q2 FY27 — Rohit Nagraj, 360 ONE Capital
AnsweredApril saw higher RM prices vs Q4; engaged suppliers on margin parity. As availability improved, securing competitively. Propylene from PDH will improve further.
Export market disruptions — Rohit Nagraj, 360 ONE Capital
AnsweredHigh freight/insurance rates. Agile approach: e.g., changed sodium nitrite formulation (added water) to reduce hazmat class, lowering shipping cost. Engaging on CIF-to-FOB, consolidation strategies.
R&D pipeline, gross margin impact — Sajal Kapoor, Antifragile Thinking
AnsweredRed ocean competition in existing chemistries (nitration, etc.); new molecules faced margin pressure from low-cost competitors. China now tightening; competition intensity improving. New molecules at better margins; entering new applications with higher purity. Results in next few years.
Flow chemistry commercialization — Sajal Kapoor, Antifragile Thinking
PartialFlow chemistry platform in NOx chemistry; batch reaction 16-18 hours now 45-52 seconds. Reduces hazardous intermediate inventory, rapid changeover. Coming next FY, not current FY. Market traction via seed samples.
Capex spend and peak debt — Vidhi Shah, C.R. Kothari & Sons
AnsweredSpent ₹1.2 Cr so far. FY27 further ₹1-1.5 Cr. Total FY27 spend ~₹3.2 Cr (site dev, construction, long-lead items). Peak debt ₹8-8.5 Cr; D/E <1x.
Polycarbonate project margin expectations — Tushar Raghatate, Omega Portfolio Advisors
DodgedDeclined to comment on integrated margin. Stated has 'formidable IRR' and banks convinced. No specifics.
Aerospace/defence applications for polycarbonate — Tushar Raghatate, Omega Portfolio Advisors
DodgedDeclined to comment; under NDA.
Phenol volumes in Q1 breakdown — Meet Vora, JM Financial
AnsweredRun-rate basis only. April spotty (maintenance shutdown preponed). Parts of quarter on stockpiled intermediates, part on bought-out propylene/benzene.
MIBK/acetone pricing ratio threshold — Meet Vora, JM Financial
PartialFirst time hearing of 1.6 ratio. Cannot align with specific number. Process is condensation + reduction; implemented divided-wall columns for efficiency. World-scale cost position.
Guidance
No explicit FY27 revenue target disclosed
LowPrior call: 'continued positive performance.' This call hints 'improving demand, visibility' but no number.
EBITDA margin expected to improve further; new asset margins inline/better than existing
MediumBased on MIBK/MIBC ramp, flow chemistry, new asset launches. But management refused to quantify margin profiles.
FY27 capex ₹3.2 Cr (of ₹11.5 Cr total); FY28 another ₹3 Cr planned
HighDebt funding closed. ₹1.2 Cr spent Q1; ₹1-1.5 Cr more in FY27. Funded via 60:40 debt:equity ratio.
Risks the call surfaced
Raw material volatility
HighPhenolics relies on propylene, benzene sourcing. April saw shortage + higher prices. Management agile but margins eroded if RM pricing power lost.
Phenol run-rate sustainability
Medium1L tonne/quarter phenol run-rate hit on 'run rate basis' only; April weak due to maintenance shutdown + propylene scarcity. Quarterly volumes may not sustain.
Project execution & capex risk
High₹11.5 Cr polycarbonate/propylene capex targeting H2 FY28-29. MIBK/MIBC & acetophenone commissioning by Q2 but pre-comm runs only. Cost/schedule slippage risk high.
R&D pipeline commercialization lag
MediumFlow chemistry, fluorination, amination projects still in R&D/customer validation. Margin uplift deferred to 'next FY, not this FY.' Customer cycles 12-24+ months.
Margin sustainability on new assets
MediumMIBK/MIBC margin profile not quantified; only 'inline or better than average AI.' Phenolics EBIT margin 23.5% driven by RM arbitrage and demand strength—both volatile.
Geopolitical & macro disruption
MediumCall explicitly flags geopolitical developments, pricing volatility. Freight, insurance rates escalating. War premium in Middle East (export market). Macro uncertainty on demand visibility.
Management
Score 7/10. Transparent on challenges (RM volatility, April shutdown, propylene scarcity) but guarded on sensitive metrics (spread specifics, new asset margins). Provided detailed operational colour (flow chemistry cycle times, customer names). Declined aerospace applications (NDA-appropriate). Q1 delivered record numbers matching call claims. Ammonia-to-amines integration completed on schedule. Capex funding closed. April weakness shows execution variability; ramp-up slower than run-rate suggests.
1 · Aug 2026
MIBK, MIBC, acetophenone commissioning; margins proof
2 · Q2 FY27
Remaining AG intermediates, alkylation plant commissioning
3 · H2 FY28-29
Polycarbonate resin plant commissioning; BPA ahead of PC
Capex-heavy trajectory (₹11.5 Cr polycarbonate) and project execution risk (FY28-29 timeline) warrant caution despite long-term upside.